1
|
Kuyama S, Yoshioka H, Kaneda H, Kataoka Y, Miura S, Katakami N, Yamanaka Y, Tamiya A, Yamada T, Yokoyama T, Hara S, Tanaka H, Fujisaka Y, Nakamura A, Azuma K, Namba M, Hata A, Sawa K, Ishikawa H, Kurata T. 330P A real-world multi-center prospective observational study of atezolizumab (Atezo) + bevacizumab (Bev) + carboplatin (CBDCA) + paclitaxel (PTX) (ABCP) in patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC after EGFR-TKIs failure. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
2
|
Tamiya M, Goto Y, Kenmotsu H, Kurata T, Murakami S, Yanagitani N, Taniguchi H, Kuyama S, Shimizu J, Yokoyama T, Shimada N, T. M, Tamiya A, Uchiyama A, Imaizumi K, Takahama T, Nishio M, Hayashi H, Shiraiwa N, Okura M, Kikkawa H, Thomaidou D, Kato T. EP08.02-115 A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
3
|
Yoshida T, Fujisaka Y, Kurata T, Yamamoto N, Thomas A, Sarholz B, Hallwachs R, Bolleddula J, Kuronita T, Moulin Correa C, Paz-Ares L. 1534P Phase II study of berzosertib + topotecan in patients with relapsed platinum (Pt)-resistant SCLC (DDRiver SCLC 250): Japanese safety run-in. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
4
|
Garassino M, Gadgeel S, Speranza G, Felip E, Esteban Gonzalez E, Domine Gomez M, Hochmair M, Powell S, Bischoff H, Peled N, Grossi F, Jennens R, Reck M, Hui R, Garon E, Kurata T, Gray J, Schwarzenberger P, Jensen E, Rodriguez Abreu D. 973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
5
|
Tachihara M, Tsujino K, Shimokawa M, Ishihara T, Hayashi H, Sato Y, Kurata T, Sugawara S, Shiraishi Y, Teraoka S, Azuma K, Daga H, Yamaguchi M, Kodaira T, satouchi M, Yamamoto N, Nakagawa K. MA06.04 Phase II Study of Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study (WJOG11619L). J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Kogure Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Saka H, Ebi N, Inoue A, Kurata T, Fujita Y, Nishii Y, Shibayama T, Itani H, Endo T, Yamamoto N, Gemma A. 1160P Survival impact of second-line immune checkpoint inhibitors in the elderly patients with advanced squamous non-small cell lung cancer: Post-hoc analysis from a CAPITAL study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
7
|
Dominguez Molina L, Kurata T, Talavera Perez A, Hauryliuk V, Garcia Pino A. Mechanism of regulation and neutralization of tRNA-phosphorylating small RelA-SpoT homologue toxins. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322093858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
8
|
Tamagawa H, Sugimoto N, Watanabe T, Satake H, Kataoka K, Kamei K, Kobayashi M, Munakata K, Fukunaga M, Kotaka M, Satoh T, Kanazawa A, Kurata T, Tomita N. P-78 A phase II study of resection followed by capecitabine plus oxaliplatin for liver metastasis of colorectal cancer (REX study): Final analysis. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
9
|
Halmos B, Cobb P, Johnson M, Jain L, Kim S, Saraf S, Lala M, Kurata T. 168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
10
|
Miura S, Azuma K, Yoshioka H, Teraoka S, Ishii H, Koyama K, Kibata K, Ozawa Y, Tokito T, Koh Y, Shimokawa T, Kurata T, Yamamoto N, Tanaka H. MA02.05 A Phase I Study of Afatinib in Combination With Osimertinib in Patients After Failure of Prior Osimertinib. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Saito G, Kogure Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Saka H, Ebi N, Inoue A, Kurata T, Yamanaka T, Ando M, Shibayama T, Itani H, Nishii Y, Fujita Y, Yamamoto N, Gemma A. 1333P Dose and schedule modifications of carboplatin plus nab-paclitaxel for elderly patients with squamous non-small cell lung cancer from the CAPITAL study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Toyozawa R, Itahashi K, Goto Y, Fujiwara Y, Okuma Y, Kurata T, Yokoyama T, Nokihara H, Yokoi T, Yamaguchi T, Shiraishi Y, Takeda M, Tokito T, Nakamura A, Hosomi Y, Ohe Y. 1292P Two single-arm, multicenter phase-II trials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603/NCCH1703). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
13
|
Gray J, Rodríguez-Abreu D, Powell S, Hochmair M, Gadgeel S, Esteban E, Felip E, Speranza G, De Angelis F, Dómine M, Cheng S, Bischoff H, Peled N, Reck M, Hui R, Garon E, Boyer M, Kurata T, Yang J, Jensen E, Souza F, Garassino M. FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.141] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
14
|
Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste J, Spigel D, Garassino M, Reck M, Senan S, Naidoo J, Rimner A, Wu YL, Gray J, Özgüroğlu M, Lee K, Newton M, Wang L, Thiyagarajah P, Antonia S. LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2281] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
15
|
Borghaei H, Langer C, Paz-Ares L, Rodriguez-Abreu D, Papadimitrakopoulou V, Garassino M, Houghton B, Kurata T, Cheng Y, Lin J, Pietanza C, Piperdi B, Gadgeel S. OA01.01 Pembrolizumab Plus Chemotherapy for Advanced NSCLC without Tumor PD-L1 Expression: Pooled Analysis of KN021G, KN189 and KN407. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Gadgeel S, Garassino M, Esteban E, Speranza G, Felip E, Hochmair M, Powell S, Cheng SS, Bischoff H, Peled N, Hui R, Reck M, Kurata T, Garon E, Boyer M, Yang J, Pietanza M, Rodríguez-Abreu D. O.03 KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab + Chemotherapy for Metastatic Nonsquamous NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.090] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
17
|
Kibata K, Izuno H, Nakahama K, Yamanaka Y, Kaneda T, Yoshioka H, Kurata T, Nomura S. Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz438.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Wu YL, Gray J, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee K, Cho B, Planchard D, Paz-Ares L, Faivre-Finn C, Vansteenkiste J, Spigel D, Taboada M, Dennis P, Özgüroğlu M, Antonia S. Three-year overall survival update from the PACIFIC trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz438.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Powell S, Abreu DR, Langer C, Tafreshi A, Paz-Ares L, Kopp HG, Rodríguez-Cid J, Kowalski D, Cheng Y, Kurata T, Awad M, Lin J, Zhao B, Pietanza M, Piperdi B, Garassino M. Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.005] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Yang JH, Ramalingam S, Lee C, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Rukazenkov Y, Murphy M, Jänne P. Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Horinouchi H, Nogami N, Saka H, Nishio M, Tokito T, Takahashi T, Kasahara K, Hattori Y, Ichihara E, Adachi N, Sawada T, Shimamoto T, Noguchi K, Pietanza M, Kurata T. Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Raben D, Faivre-Finn C, Spigel D, Daniel D, Villegas A, Vincente D, Hui R, de Castro Carpeno J, Murakami S, Paz-Ares L, Özgüroğlu M, Kurata T, Chiappori A, Lee K, de Wit M, Poole L, Wadsworth C, Dennis P, Antonia S. PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.08.057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Hata A, Katakami N, Nishino K, Mori M, Yokoyama T, Kurata T, Tachihara M, Takase N, Daga H, Kijima T, Morita S, Sakai K, Nishio K, Satouchi M, Negoro S. Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSIME) failure for aDvanced EGFR-mutant non-small cell lung cancer (NSCLC): A multicenter prospective single arm phase II study (ABCD-study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Iwama E, Sakai K, Azuma K, Harada D, Nosaki K, Hotta K, Nishio M, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I. P2.13-18 A Multicenter Prospective Biomarker Study to Explore Mechanisms of Afatinib Resistance Based on Digita PCR and Next-Generation Sequencing. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee K, De Wit M, Cho B, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim Y, Karapetis C, Hiret S, Ostoros G, Kubota K, Gray J, Paz-Ares L, De Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel D, Wadsworth C, Taboada M, Dennis P, Özgüroğlu M. PL02.01 Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Carcereny E, Felip E, Reck M, Patel J, Heist R, Balmanoukian A, Chow L, Paz-Ares L, Qiu J, Coleman S, Mocci S, Sandler A, Kurata T, Shepherd F. OA 17.02 Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1–Selected Patients With Advanced NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.428] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
27
|
Cho B, Chewaskulyong B, Lee K, Dechaphunkul A, Sriuranpong V, Imamura F, Ohe Y, Nogami N, Kurata T, Okamoto I, Zhou C, Cheng Y, Cho E, Jye V, Lee JS, Mann H, Saggese M, Reungwetwattana T. Osimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx729.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Ono A, Takahashi T, Niho S, Yoshida T, Akimoto T, Sakamaki K, Seto T, Nishio M, Yamamoto N, Hida T, Okamoto H, Kurata T, Satouchi M, Goto K, Yamanaka T, Ohe Y. MA 17.06 Safety Data from Randomized Phase II Study of CDDP+S-1 vs CDDP+PEM Combined with TRT for Locally Advanced Non-Squamous NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
29
|
Kibata K, Yokoi T, Yoshioka H, Kurata T, Nomura S. Efficacy and toxicity of nivolumab in real-world; including nivolumab rechallenge. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Saito T, Tsuta K, Kinoshita Y, Ryota H, Miyata N, Takeyasu Y, Fukumoto K, Matsui H, Taniguchi Y, Yanagimoto H, Yokoi T, Kurata T, Murakawa T. P-148COMPARISON STUDY OF PD-L1 IMMUNOHISTOCHEMISTRY ASSAYS WITH 22C3 AND 28-8 FOR NON-SMALL CELL LUNG CANCERS: HOW CAN THE RESULTS BE TRANSLATED BETWEEN THE TWO? Interact Cardiovasc Thorac Surg 2017. [DOI: 10.1093/icvts/ivx280.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Niho S, Yoshida T, Akimoto T, Sakamaki K, Takahashi T, Seto T, Nishio M, Yamamoto N, Hida T, Okamoto H, Kurata T, Satouchi M, Goto K, Yamanaka T, Ohe Y. Safety data from randomized phase II study of cisplatin (CDDP)+S-1 versus CDDP+pemetrexed (PEM) combined with thoracic radiotherapy (TRT) for locally advanced non-squamous (non-sq) non-small cell lung cancer (NSCLC): SPECTRA study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx379.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Peters S, Carcereny Costa E, Garassino M, Christoph D, Kurata T, Chaft J, Johnson M, Mocci S, Gettinger S, Felip E. Atezolizumab as first-line (1L) therapy for advanced non-small cell lung cancer (NSCLC) in PD-L1–selected patients: Efficacy data from the BIRCH trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx091.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Eberhardt W, Garassino MC, Rizvi NA, Besse B, Jänne PA, Peters S, Keong Toh C, Kurata T, Carcereny Costa E, Koczywas M, Felip Font E, Chaft J, Qiu J, Kowanetz M, Zou W, Coleman S, Mocci S, Sandler A, Gettinger S, Johnson ML. Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study. Pneumologie 2017. [DOI: 10.1055/s-0037-1598277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- W Eberhardt
- Universitätsklinikum Essen, Ruhrlandklinik, West German Cancer Center, Universität Duisburg-Essen
| | - MC Garassino
- Fondazione Irccs Istituto Nazionale Dei Tumori, Thoracic Oncology Unit
| | - NA Rizvi
- New York-Presbyterian/Columbia University Medical Center
| | - B Besse
- Gustave Roussy, Villejuif France and Paris Sud University
| | | | | | | | - T Kurata
- Kansai Medical University Hirakata Hospital
| | - E Carcereny Costa
- Catalan Institute of Oncology Badalona – Germans Trias I Pujol Hospital Badalona
| | | | | | - J Chaft
- Memorial Sloan Kettering Cancer Center
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Iwama E, Sakai K, Azuma K, Harada T, Harada D, Nosaki K, Hotta K, Ohyanagi F, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations. Ann Oncol 2017; 28:136-141. [DOI: 10.1093/annonc/mdw531] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
35
|
Kogure Y, Saka H, Takiguchi Y, Atagi S, Kurata T, Ebi N, Inoue A, Kubota K, Takenoyama M, Seto T, Kada A, Yamanaka T, Ando M, Yamamoto N, Gemma A, Ichinose Y. Carboplatin (Cb) plus nab-paclitaxel (PTX) versus docetaxel (D) for elderly squamous (Sq) non-small cell lung cancer (NSCLC) (CAPITAL study). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.99] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Morita D, Hirabayashi K, Katsuyama Y, Morokawa H, Motobayashi M, Kurata T, Shigemura T, Tanaka M, Inaba Y, Koike K, Nakazawa Y. Viral load and ganciclovir (GCV) concentration in cerebrospinal fluid of patients successfully treated with GCV or valGCV for human herpesvirus 6 encephalitis/myelitis following umbilical cord blood transplantation. Transpl Infect Dis 2016; 18:773-776. [PMID: 27459097 DOI: 10.1111/tid.12579] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2016] [Revised: 03/23/2016] [Accepted: 05/10/2016] [Indexed: 11/26/2022]
Abstract
We describe successful treatment of 3 cases of human herpesvirus 6 (HHV-6) encephalitis/myelitis following cord blood transplantation (CBT). Ganciclovir (GCV) (10 mg/kg/day) reduced HHV-6 load to undetectable levels in cerebrospinal fluid (CSF). Early dose reduction in the presence of HHV-6 detectable in CSF resulted in an increased HHV-6 load. GCV was capably shifted to valganciclovir (VGCV) with an almost equivalent concentration. GCV/VGCV may be effective for HHV-6 encephalitis/myelitis after CBT, although HHV-6 load in CSF should be monitored.
Collapse
Affiliation(s)
- D Morita
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - K Hirabayashi
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - Y Katsuyama
- Department of Pharmacy, Shinshu University Hospital, Matsumoto, Japan
| | - H Morokawa
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - M Motobayashi
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - T Kurata
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - T Shigemura
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - M Tanaka
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - Y Inaba
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - K Koike
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - Y Nakazawa
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
| |
Collapse
|
37
|
Kurata T, Fushida S, Tsukada T, Kinoshita J, Oyama K, Ohta T. P-206 Effects of eribulin mesilate for tumor progression and fibrosis in gastric cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Fushida S, Saito H, Kurata T, Kinoshita J, Oyama K, Miyashita T, Ohta T. P-034 The potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated by preoperative docetaxel, cisplatin, and S-1. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Ramalingam S, Yang JH, Lee C, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Jänne P. LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30324-0] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
40
|
Iwama E, Sakai K, Azuma K, Nosaki K, Harada D, Hotta K, Ohyanagi F, Kurata T, Akamatsu H, Goto K, Fukuhara T, Nakanishi Y, Nishio K, Okamoto I. 484PD A multicenter prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv533.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Shimizu T, Okano N, Kurata T, Naruge D, Fujisaka Y, Kitamura H, Nagashima F, Nakagawa K, Furuse J. 128O Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in Japanese patients with advanced solid tumors. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv521.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Besse B, Johnson M, Janne P, Garassino M, Eberhardt W, Besse B, Johnson M, Janne P, Garassino M, Eberhardt W, Peters S, Toh C, Kurata T, Li Z, Kowanetz M, Mocci S, Sandler A, Rizvi N. 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31938-4] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Sakashita K, Kato I, Daifu T, Saida S, Hiramatsu H, Nishinaka Y, Ebihara Y, Ma F, Matsuda K, Saito S, Hirabayashi K, Kurata T, Uyen LTN, Nakazawa Y, Tsuji K, Heike T, Nakahata T, Koike K. In vitro expansion of CD34(+)CD38(-) cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia. Leukemia 2015; 29:606-14. [PMID: 25102944 DOI: 10.1038/leu.2014.239] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2013] [Revised: 07/09/2013] [Accepted: 07/24/2014] [Indexed: 12/11/2022]
Abstract
Using serum-containing culture, we examined whether AGM-S3 stromal cells, alone or in combination with hematopoietic growth factor(s), stimulated the proliferation of CD34(+) cells from patients with juvenile myelomonocytic leukemia (JMML). AGM-S3 cells in concert with stem cell factor plus thrombopoietin increased the numbers of peripheral blood CD34(+) cells to approximately 20-fold of the input value after 2 weeks in nine JMML patients with either PTPN11 mutations or RAS mutations, who received allogeneic hematopoietic transplantation. Granulocyte-macrophage colony-stimulating factor (GM-CSF) also augmented the proliferation of JMML CD34(+) cells on AGM-S3 cells. The expansion potential of CD34(+) cells was markedly low in four patients who achieved spontaneous hematological improvement. A large proportion of day-14-cultured CD34(+) cells were negative for CD38 and cryopreservable. Cultured JMML CD34(+)CD38(-) cells expressed CD117, CD116, c-mpl, CD123, CD90, but not CXCR4, and formed GM and erythroid colonies. Day-7-cultured CD34(+) cells from two of three JMML patients injected intrafemorally into immunodeficient mice stimulated with human GM-CSF after transplantation displayed significant hematopoietic reconstitution. The abilities of OP9 cells and MS-5 cells were one-third and one-tenth, respectively, of the value obtained with AGM-S3 cells. Our culture system may provide a useful tool for elucidating leukemogenesis and for therapeutic approaches in JMML.
Collapse
MESH Headings
- ADP-ribosyl Cyclase 1/genetics
- ADP-ribosyl Cyclase 1/metabolism
- Adolescent
- Animals
- Antigens, CD34/genetics
- Antigens, CD34/metabolism
- Cell Proliferation/drug effects
- Clone Cells
- Coculture Techniques
- Embryonic Stem Cells/drug effects
- Embryonic Stem Cells/metabolism
- Embryonic Stem Cells/pathology
- GTP Phosphohydrolases/genetics
- GTP Phosphohydrolases/metabolism
- Gene Expression Regulation, Leukemic
- Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology
- Hematopoietic Stem Cells/drug effects
- Hematopoietic Stem Cells/metabolism
- Hematopoietic Stem Cells/pathology
- Humans
- Leukemia, Myelomonocytic, Juvenile/genetics
- Leukemia, Myelomonocytic, Juvenile/metabolism
- Leukemia, Myelomonocytic, Juvenile/pathology
- Membrane Proteins/genetics
- Membrane Proteins/metabolism
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Mutation
- Neoplastic Stem Cells/metabolism
- Neoplastic Stem Cells/pathology
- Neoplastic Stem Cells/transplantation
- Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics
- Protein Tyrosine Phosphatase, Non-Receptor Type 11/metabolism
- Proto-Oncogene Proteins/genetics
- Proto-Oncogene Proteins/metabolism
- Proto-Oncogene Proteins p21(ras)
- Signal Transduction
- Stromal Cells/drug effects
- Stromal Cells/metabolism
- Stromal Cells/pathology
- ras Proteins/genetics
- ras Proteins/metabolism
Collapse
Affiliation(s)
- K Sakashita
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - I Kato
- Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - T Daifu
- Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - S Saida
- Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - H Hiramatsu
- Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Y Nishinaka
- Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan
| | - Y Ebihara
- 1] Department of Pediatric Hematology/Oncology, Research Hospital, Institute of Medical Science, University of Tokyo, Minato-ku, Japan [2] Division of Stem Cell Processing, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo, Minato-ku, Japan
| | - F Ma
- 1] Division of Stem Cell Processing, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo, Minato-ku, Japan [2] Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, China
| | - K Matsuda
- Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan
| | - S Saito
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - K Hirabayashi
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - T Kurata
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - L T N Uyen
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - Y Nakazawa
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - K Tsuji
- 1] Department of Pediatric Hematology/Oncology, Research Hospital, Institute of Medical Science, University of Tokyo, Minato-ku, Japan [2] Division of Stem Cell Processing, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo, Minato-ku, Japan [3] Department of Pediatrics, Shinshu Ueda Medical Center, National Hospital Organization, Ueda, Japan
| | - T Heike
- Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - T Nakahata
- Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan
| | - K Koike
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| |
Collapse
|
44
|
Sakiyama T, Tsurutani J, Iwasa T, Kawakami H, Nonagase Y, Yoshida T, Tanaka K, Fujisaka Y, Kurata T, Komoike Y, Nishio K, Nakagawa K. A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer. Br J Cancer 2015; 112:819-24. [PMID: 25654665 PMCID: PMC4453950 DOI: 10.1038/bjc.2015.10] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2014] [Revised: 12/12/2014] [Accepted: 12/21/2014] [Indexed: 02/07/2023] Open
Abstract
Background: We evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, recommended dose for phase II (P2RD), and preliminary anticancer activity of a combination eribulin and S-1 therapeutic in metastatic breast cancer patients pretreated with anthracycline and taxane. Method: Patients aged 20–74 years were recruited. In level 1, patients received S-1 (65 mg m−2) from day 1 to 14, and eribulin (1.1 mg m−2) on day 1 and 8 in a 21-day cycle. In level 2, eribulin was increased to 1.4 mg m−2. In level 3, S-1 was increased to 80 mg m−2. Results: Twelve patients were enrolled into three cohorts. Planned dose escalation was completed, with one case exhibiting dose-limiting toxicity (grade 3 hypokalaemia) at level 3, without reaching the MTD. The P2RD was determined to be level 2 (eribulin 1.4 mg m−2 and S-1 65 mg m−2). The most common grade 3 or 4 toxicity was neutropenia (83.3%), followed by febrile neutropenia (25.0%). Five of eleven patients (41.7%) with measurable disease had a partial response. Pharmacokinetics were characterised by dose-dependent elimination and nonlinear exposure. Conclusion: Dose level 3 was not tolerated owing to febrile neutropenia development. Thus, intermediate dose level 2 was recommended for further evaluation. Preliminary antitumour activity warrants further investigation in this setting.
Collapse
Affiliation(s)
- T Sakiyama
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - J Tsurutani
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - T Iwasa
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - H Kawakami
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - Y Nonagase
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - T Yoshida
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - K Tanaka
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - Y Fujisaka
- Clinical Research Center, Osaka Medical Collage Hospital, 2-7 Daigaku-cho, Takatsuki 569-8686, Japan
| | - T Kurata
- Department of Thoracic Oncology, Kansai Medical University Hirakata Hospital, 2-3-1 Shinmachi, Hirakata 573-1191, Japan
| | - Y Komoike
- Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - K Nishio
- Department of Genome Biology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - K Nakagawa
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| |
Collapse
|
45
|
Abo H, Okamoto K, Anraku M, Otsuki N, Sakata M, Icenogle J, Zheng Q, Kurata T, Kase T, Komase K, Takeda M, Mori Y. Development of an improved RT-LAMP assay for detection of currently circulating rubella viruses. J Virol Methods 2014; 207:73-7. [PMID: 24972365 DOI: 10.1016/j.jviromet.2014.06.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2014] [Revised: 06/12/2014] [Accepted: 06/17/2014] [Indexed: 10/25/2022]
Abstract
Rubella virus is the causative agent of rubella. The symptoms are usually mild, and characterized by a maculopapular rash and fever. However, rubella infection in pregnant women sometimes can result in the birth of infants with congenital rubella syndrome (CRS). Global efforts have been made to reduce and eliminate CRS. Although a reverse transcription-loop-mediated isothermal amplification (RT-LAMP) assay for detection of rubella virus has been reported, the primers contained several mismatched nucleotides with the genomes of currently circulating rubella virus strains. In the present study, a new RT-LAMP assay was established. The detection limit of this assay was 100-1000PFU/reaction of viruses for all rubella genotypes, except for genotype 2C, which is not commonly found in the current era. Therefore, the new RT-LAMP assay can successfully detect all current rubella virus genotypes, and does not require sophisticated devices like TaqMan real-time PCR systems. This assay should be a useful assay for laboratory diagnosis of rubella and CRS.
Collapse
Affiliation(s)
- H Abo
- Laboratory of Rubella, Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, 4-7-1 Gakuen, Musashimurayama, 208-0011, Tokyo, Japan
| | - K Okamoto
- Laboratory of Rubella, Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, 4-7-1 Gakuen, Musashimurayama, 208-0011, Tokyo, Japan.
| | - M Anraku
- Laboratory of Rubella, Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, 4-7-1 Gakuen, Musashimurayama, 208-0011, Tokyo, Japan
| | - N Otsuki
- Laboratory of Rubella, Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, 4-7-1 Gakuen, Musashimurayama, 208-0011, Tokyo, Japan
| | - M Sakata
- Laboratory of Rubella, Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, 4-7-1 Gakuen, Musashimurayama, 208-0011, Tokyo, Japan
| | - J Icenogle
- Measles, Mumps, Rubella and Herpes Virus Laboratory Branch, Division of Viral Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
| | - Q Zheng
- Measles, Mumps, Rubella and Herpes Virus Laboratory Branch, Division of Viral Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
| | - T Kurata
- Virology Division, Department of Infectious Diseases, Osaka Prefectural Institute of Public Health, 3-69, Nakamichi, 1-chome, Higashinari-ku, Osaka 537-0025, Japan
| | - T Kase
- Virology Division, Department of Infectious Diseases, Osaka Prefectural Institute of Public Health, 3-69, Nakamichi, 1-chome, Higashinari-ku, Osaka 537-0025, Japan
| | - K Komase
- Laboratory of Rubella, Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, 4-7-1 Gakuen, Musashimurayama, 208-0011, Tokyo, Japan
| | - M Takeda
- Laboratory of Rubella, Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, 4-7-1 Gakuen, Musashimurayama, 208-0011, Tokyo, Japan
| | - Y Mori
- Laboratory of Rubella, Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, 4-7-1 Gakuen, Musashimurayama, 208-0011, Tokyo, Japan
| |
Collapse
|
46
|
Kurata T, Ono M, Kozono K, Fukuyoshi R, Sato S, Toyofuku F. SU-E-J-66: Evaluation of a Real-Time Positioning Assistance Simulator System for Skull Radiography Using the Microsoft Kinect. Med Phys 2014. [DOI: 10.1118/1.4888118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
47
|
Fukuyoshi R, Kurata T, Sato S, Kozono K, Ono M, Toyofuku F. SU-E-I-03: A Kinect-Based Method of Bone and Soft Tissue Image Separation Using Object Thickness Measurement. Med Phys 2014. [DOI: 10.1118/1.4887951] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
48
|
Matsuda K, Nakazawa Y, Iwashita C, Kurata T, Hirabayashi K, Saito S, Tanaka M, Yoshikawa K, Yanagisawa R, Sakashita K, Sasaki S, Honda T, Koike K. Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia. Leukemia 2014; 28:1545-8. [PMID: 24496301 DOI: 10.1038/leu.2014.58] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- K Matsuda
- Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan
| | - Y Nakazawa
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - C Iwashita
- Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan
| | - T Kurata
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - K Hirabayashi
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - S Saito
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - M Tanaka
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - K Yoshikawa
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - R Yanagisawa
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - K Sakashita
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| | - S Sasaki
- Department of Pediatrics, Hirosaki University School of Medicine, Hirosaki, Japan
| | - T Honda
- Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan
| | - K Koike
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
| |
Collapse
|
49
|
Murakami H, Kurata T, Onozawa Y, Watanabe J, Ono A, Takahashi T, Yamamoto N, Fujisaka Y, Kiyota H, Hayashi H, Tanaka K, Nakagawa K, Kuroda S. An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2014; 73:623-30. [PMID: 24477603 PMCID: PMC3931931 DOI: 10.1007/s00280-014-2388-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2013] [Accepted: 01/13/2014] [Indexed: 11/27/2022]
Abstract
PURPOSE To determine ombrabulin's maximum tolerated dose and dose recommended for Japanese patients with advanced solid tumors and to assess its antitumor activity and overall safety and pharmacokinetic profiles. METHODS This was a multi-center, open-label, sequential-cohort, dose-escalation phase I study of ombrabulin, a vascular disrupting agent, administered once every 3 weeks. Patients were treated with 15.5, 25, 35, or 50 mg/m(2) ombrabulin over a 30-min intravenous infusion. The recommended dose was the highest dose at which <33 % of all evaluable patients experienced dose-limiting toxicities (DLTs) during the first treatment cycle or 50 mg/m(2) (recommended in Caucasian patients) if the previous definition was not met. RESULTS Fifteen patients were treated. No DLT occurred with 15.5, 25, or 35 mg/m(2) ombrabulin. In the 50 mg/m(2) group, one patient had Grade 3 lymphopenia, and another experienced Grade 2 hypertension and Grade 3 diarrhea judged as DLTs. The most frequent related adverse events in this group were diarrhea, nausea, and hypertension. Two patients had Grade 3 anemia, one at the 15.5 mg/m(2) and the other at the 50 mg/m(2). No AEs necessitating dose reduction or Grade 4 AEs were observed. Overall, five patients had stable disease. Pharmacokinetic parameters were comparable to those in non-Japanese patients. CONCLUSIONS Ombrabulin treatment once every 3 weeks was well tolerated in Japanese patients with advanced solid tumors. The dose recommended is 50 mg/m(2), as in Caucasian patients. The safety and pharmacokinetic profiles were comparable between Japanese and Caucasian patients (funded by Sanofi; ClinicalTrials.gov number, NCT00968916).
Collapse
Affiliation(s)
- H Murakami
- Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411-8777, Japan,
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Fujisaka Y, Kurata T, Tanaka K, Kudo T, Okamoto K, Tsurutani J, Kaneda H, Kitamura C, Namiki M, Nakagawa K. Phase I Study of Amatuximab in Patients with Advanced Solid Tumors. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.79] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|